ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2306

Prevalence and Clinical Significance of the Gastrointestinal Fat Halo Sign in Patients with Psoriatic Arthritis: A Cross-Sectional Study

Amir Haddad1, Kathrien Mousa1, Kateryna Milman1, Najwan Nassrallah1, Devy Zisman2 and Sharbell Hashoul3, 1Carmel Medical Centre, Haifa, Israel, 2Carmel Medical Center, Haifa, Israel, 3The Faculty of Humanities and Social Sciences. Uno Academic College, Haifa, Israel

Meeting: ACR Convergence 2025

Keywords: Computed tomography (CT), Imaging, Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2305–2337) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: The existence of a gut-joint axis is widely described in spondyloarthritis, linking intestinal dysbiosis, subclinical gut inflammation, and arthritis. The fat halo sign is believed to arise from chronic inflammation, leading to transmural edema and infiltration of the bowel wall by inflammatory cells and fat. This radiologic finding has a high prevalence in patients with inflammatory bowel disease(IBD). This study aims to define the prevalence of the fat halo sign in a well-defined cohort of patients with psoriatic arthritis (PsA) and assess its potential clinical significance.

Methods: This is a cross-sectional study involving PsA patients followed prospectively from a collaborative site of an international cohort. All patients fulfilled the CASPAR criteria. Patients who have undergone routine abdominal CT scan for various clinical indications constituted the study population. Two radiologists have independently recorded the presence of the fat halo sign in the stomach, terminal ileum, and the ascending/transverse/descending colon and rectum. Demographics and disease characteristics of patients with positive fat halo were compared to patients without fat halo using descriptive statistics as appropriate.

Results: Of the 328 patients followed, 101 completed an abdominal CT scan. The mean age was 63.7±15 of whom 49 (48.5%) were males with a disease duration of 8.4±8.7 years, 19% on non-steroidal anti-inflammatory drugs, 55% were on disease-modifying anti-rheumatic drugs and 57% were on biologics. 3.9% had a history of IBD, and 4.2% had a history of uveitis. 38/101 (37.6%) patients had a positive halo sign in at least one section (as illustrated in Figures 1 and 2). The presence of halo sign was more common in males (65.8 vs. 31.8%, p=0.007) and more likely in patients with nail lesions (31.6 vs 15.9%, p=0.06). Other patient’s demographic and disease characteristics, disease activity parameters and treatment regimen were not statistically different.

Conclusion: Fat halo is common in patients with psoriatic arthritis and was observed in 38% of patients, of whom only a minority had IBD. It was more frequent in males, however, not associated with any of other patient’s demographics, disease characteristics, disease activity parameters or treatment regimen.

Supporting image 1Contrast-enhanced coronal CT image shows fatty infiltration within the bowel wall of the descending colon at the level of the left colic flexure.

Supporting image 2Non-contrast axial CT image shows fatty infiltration within the bowel wall of the ascending colon at the level of the right colic flexure


Disclosures: A. Haddad: AbbVie/Abbott, 6, AstraZeneca, 6, Janssen, 6, Novartis, 6; K. Mousa: None; K. Milman: None; N. Nassrallah: None; D. Zisman: AbbVie/Abbott, 1, 6, AstraZeneca, 6, Eli Lilly, 6, GlaxoSmithKlein(GSK), 1, Neopharm, 1, 6, Novartis, 6, Pfizer, 1, 5; S. Hashoul: None.

To cite this abstract in AMA style:

Haddad A, Mousa K, Milman K, Nassrallah N, Zisman D, Hashoul S. Prevalence and Clinical Significance of the Gastrointestinal Fat Halo Sign in Patients with Psoriatic Arthritis: A Cross-Sectional Study [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/prevalence-and-clinical-significance-of-the-gastrointestinal-fat-halo-sign-in-patients-with-psoriatic-arthritis-a-cross-sectional-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-and-clinical-significance-of-the-gastrointestinal-fat-halo-sign-in-patients-with-psoriatic-arthritis-a-cross-sectional-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology